Cadrenal Therapeutics
Developer of anticoagulation candidates for high-risk hospital and cardiovascular care.
Something off on this page? Send us feedback.
Profile
Develops anticoagulation and thrombo-inflammation candidates for high-risk hospital and cardiovascular patients, seeking future revenue from approvals, product sales, and partnership or royalty arrangements. Its lean model depends on third parties and licensed or regionally split rights.
Develops CAD-1005, tecarfarin, and frunexian for high-risk anticoagulation needs across heparin-induced thrombocytopenia, complex chronic care, and acute hospital settings. No candidate currently has regulatory approval or generates product revenue; prospective economics depend on successful development and approval, product sales, and licensing, co-development, monetization, or royalty arrangements.
Operates through a lean, outsourced model, relying on third parties for clinical, regulatory, and manufacturing work while pursuing pharmaceutical partners for the cardiovascular portfolio. CAD-1005's worldwide rights depend on an Old Dominion University license; frunexian rights exclude China, where Haisco controls development and commercialization.
Company facts
Key statistics
Analysts
No analyst consensus on record.
Earnings
EPSReportedEstimate
RevenueReportedEstimate
Financials
Balance sheet, Jun 30, 2026Cash & short-term investments $2.4M · Total debt $0 · Total assets $5.6M · Shareholders' equity $4.1M
- Revenue
- $0
- Operating income
- −$3.3M
- Net income
- −$3.3M
Dividends
No dividends on record.
Ownership
| Institutions17 holders · as of Mar 31, 2026 | 2.55% | 90.9K shares | |
| Insiders2 holders · as of Jul 1, 2026 | 2.81% | 100.3K shares | |
| Otherremainder | 94.64% | 3.38M shares |
3.57M company shares as of Sep 1, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Quang X. PhamInsiderdirector, 10 percent owner, officer: Chairman and CEO | 2.76% | 98,589 | Form 4filed Jul 1, 2026 ↗ |
Vanguard Capital Management LLCInstitution | 1.27% | 45,201 | 13Fas of Mar 31, 2026 |
Geode Capital Management, LLCInstitution | 0.61% | 21,626 | 13Fas of Mar 31, 2026 |
Vanguard Fiduciary Trust CoInstitution | 0.23% | 8,311 | 13Fas of Mar 31, 2026 |
JPMorgan Chase & CoInstitution | 0.21% | 7,500 | 13Fas of Mar 31, 2026 |
| See all 24 → | |||
13F — a manager's quarterly holdings · Form 4 — an insider's transaction report
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jun 29, 2026 | Quang X. Pham | director, 10 percent owner, officer: Chairman and CEO | −7,400 | $3.03 |
| Jun 26, 2026 | Quang X. Pham | director, 10 percent owner, officer: Chairman, CEO and Interim CFO | −9,029 | $3.05 |
| Jun 25, 2026 | Quang X. Pham | director, 10 percent owner, officer: Chairman, CEO and Interim CFO | −2,127 | $3.00 |
| Jun 23, 2026 | Quang X. Pham | director, 10 percent owner, officer: Chairman, CEO and Interim CFO | −2,277 | $3.20 |
| Jun 22, 2026 | Quang X. Pham | director, 10 percent owner, officer: Chairman, CEO and Interim CFO | −9,167 | $3.55 |
Peers
- Pfizer
Argatroban anchors HIT care; Eliquis overlaps in chronic anticoagulation.
- Bristol-Myers Squibb
Eliquis is the leading branded DOAC against tecarfarin's target use.
- Johnson & Johnson
Xarelto supplies a broad DOAC alternative in chronic cardiovascular care.
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Cadrenal Therapeutics | $1.40 | −19.77% | $6.2M | — | — | — | — |
| Pfizer | $28.48 | +0.07% | $162.21B | 37.6 | 10.2 | 2.5 | +2.6% |
| Bristol-Myers Squibb | $66.93 | +0.19% | $136.47B | 14.7 | 10.5 | 2.8 | +5.7% |
| Johnson & Johnson | $266.13 | +0.10% | $640.67B | 30.8 | 22.3 | 6.5 | +6.6% |
| Median | 30.8 | 10.5 | 2.8 | +5.7% |